Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT06851910
Recruiting Observational

Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia

NCT06851910 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital Universitari de Bellvitge
Phase
Observational
Started
2025-04-21
Last updated
2026-09-15

Condition(s) studied

Trigeminal Neuralgia

Investigational drug(s) / intervention(s)

Lacosamide →

Lacosamide: Patients will be included if they are prescribed intravenous lacosamide for their trigeminal neuralgia exacerbation

Study summary

This prospective observational study evaluates the effectiveness and safety of intravenous lacosamide as a rescue treatment for acute pain in patients presenting to the emergency department with trigeminal neuralgia

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
All patients diagnosed with trigeminal neuralgia who present to the emergency department of Hospital de Bellvitge for an acute pain exacerbation and are prescribed intravenous lacosamide as symptomatic pain treatment, according to the treating physician's discretion, will be considered for inclusion. Inclusion Criteria: * Diagnosis of classical or idiopathic trigeminal neuralgia according to the criteria of the International Classification of Headache Disorders (ICHD-3). * Age over 18 years. * Signed informed consent. Exclusion Criteria: * Contraindication for treatment with lacosamide (previous hypersensitivity reaction, known atrioventricular block). * Mental or psychiatric illness that interferes with the ability to understand and sign the informed consent. * Language barrier. * Lack of cooperation.

Primary outcome measure(s)

  • Pain relief — 2 hours post-infusion
    Measured by the Numerical Pain Rating Scale (NPRS), which ranges from 0 (no pain) to 10 (worst imaginable pain). A decrease of ≥50% from baseline indicates improvement in pain intensity.
  • Adverse effects — Through study completion, an average of 1 week
    Incidence of adverse effects

Trial sites (1)

FacilityCityRegionStatus
Hospital de Bellvitge L'Hospitalet de Llobregat Barcelona Recruiting

More Hospital Universitari de Bellvitge trials in Spain

Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Surgery (SLIDY) Recruiting
Sarcopenia in Colorectal Cancer Patients, Intervention Study Recruiting
Usefulness of ICG Angiography-Guided Thyroidectomy for Preserving Parathyroid Function Recruiting
Endoscopic Ultrasound-Guided Gastroenterostomy Nationwide: Prospective Registry. Recruiting
Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy . Recruiting

Other trials for the same condition

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06851910 on ClinicalTrials.gov ↗ ← All trials in Spain